

MISCELLANEOUS DESIGN — 2307371

Application number

2307371

Registration number

TMA1356152

Type(s)

Design

Category

Trademark

CIPO Status

REGISTERED

TM5 status

LIVE/REGISTRATION/Issued
and Active



The trademark application has
been registered with the Office.

Filed

2024-01-29

Registered

2025-10-31

Registration Expiry Date

2035-10-31

Registered Owner

Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192
UNITED STATES OF
AMERICA

Agent

TORYS LLP
SUITE 3000
79 WELLINGTON ST. W.
BOX 270, TD CENTRE
TORONTO
ONTARIO M5K1N2

Documents

[View documents](#)

Vienna information (Code & Description)

- | | |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 15.1.13 | Propellers, ventilators, blowers, turbines, burners -- Note: Includes all kinds of propellers, including those for aircraft or ships. |
| 1.15.23 | Vortices, rotary movements, tornadoes -- Note: Not including astronomical orbits (1.13.1), atomic orbits (1.13.1), concentric circles (26.1.4 or 26.1.5) and spirals (26.1.5). |
| 26.2.3 | Sectors of circles or ellipses (except 26.2.7) |
| 26.2.5 | Joined or intersecting segments or sectors of circles or ellipses |
| A 26.2.24 | Segments or sectors of circles or ellipses, semi-circles or semi-ellipses with dark surfaces or parts of surfaces |

Goods (Nice class & Statement)

- | | |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5 | (1) Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders, Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines; |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Action History

Action	Action date	Due date	Comments
Filed	2024-01-29		
Created	2024-01-29		
Formalized	2024-01-29		
Pre-Assessment Letter Sent	2024-02-08		Goods or Services Not Acceptable
Search Recorded	2025-07-07		
Approved	2025-07-15		APPROVED BY PROGRAM EX200M1
Approval Notice Sent	2025-07-15		APPROVED BY PROGRAM EX200M1
Advertised	2025-08-13		Vol.72 Issue 3694
Registration Pending	2025-10-31		
Registered	2025-10-31	2035-10-31	